Research methods · 11 min
Reading peptide research with a critical eye
A practical framework for separating trial design, observed outcomes and unsupported interpretation.
3 primary sourcesRead articleResearch library
Good science
should make sense.
See what was studied, how researchers interpreted the result and what the evidence does not establish.
Research methods · 8 min
Tracking wearable data without overstating what it means
A research-methods guide to baselines, device validity, missing data and clearly defined endpoints.
2 regulatory sourcesRead article
Laboratory fundamentals · 6 min
What a Certificate of Analysis can—and cannot—tell you
How identity, purity, analytical method and batch provenance work together.
2 standards sourcesRead article
Protocol series · 8 min
Compound integrity from storage to analysis
A documentation-first approach to controlled storage and laboratory handling.
3 standards sourcesRead articleClinical-trial index · 9 min
How EternaGen reports published clinical-trial information
Our standard for factual summaries, source citation and separation from commerce.
8 compound evidence areasRead article
Clinical-trial review · 12 min
Tesamorelin trials: population, endpoint and follow-up
A plain-language reading of the phase 3 programme in adults living with HIV and excess abdominal fat.
3 primary trial reportsRead articleShowing 6 of 20 research guides.
Clinical study index
See how the study was designed.
Review who took part, what researchers measured and what the result can—and cannot—tell us. Every entry links to its original source.
Published research PubMed indexed
Tesamorelin · Randomized human trialStudy 01
Growth hormone-releasing factor in adults with HIV-associated abdominal fat accumulation
Falutz et al. J Acquir Immune Defic Syndr. 2010. PMID 20101189
Randomized, double-blind, placebo-controlled study with a 12-month extension · 404 adults living with HIV and excess abdominal fat in the context of antiretroviral therapy
Published research PubMed indexed
Retatrutide · Phase 2 human trialStudy 02
Triple-hormone-receptor agonist retatrutide studied in adults with obesity
Jastreboff et al. N Engl J Med. 2023. PMID 37366315
Randomized, double-blind, placebo-controlled phase 2 trial over 48 weeks · 338 adults with obesity
Published research PubMed indexed
Retatrutide · Phase 2 human trialStudy 03
Retatrutide studied in adults with type 2 diabetes
Rosenstock et al. Lancet. 2023. PMID 37385280
Randomized, double-blind, double-dummy, placebo- and active-controlled phase 2 trial with 36-week follow-up · 281 adults with type 2 diabetes enrolled across 42 US research and health-care centres
Published research PubMed indexed
CJC-1295 · Early human researchStudy 04
CJC-1295 pharmacokinetics and pharmacodynamics in healthy adults
Teichman et al. J Clin Endocrinol Metab. 2006. PMID 16352683
Two randomized, placebo-controlled, double-blind ascending-dose studies lasting 28 and 49 days · Healthy adults aged 21 to 61 years
Showing 4 of 14 study records.
Browse the full study indexEducational source index only. Publication summaries do not constitute medical advice, therapeutic claims or recommendations for human or veterinary use.
Go to the source
Check the original record.
Use these independent databases and reporting frameworks to confirm study details, publication status and version history.
External records can change after our review date. Confirm the record status, version history and publication details at the linked source.
Watch and learn
Helpful explanations.
Original sources first.
These physician, university and journal channels can make difficult ideas easier to understand. Use them as a starting point, then check the paper, population and methods yourself.
Inclusion is not endorsement or medical advice.Videos are included for science communication and research literacy. They do not establish product quality, regulatory status, clinical suitability or an individual course of care.